Medinotec Inc.

PINK:MDNC USA Medical Devices
Market Cap
$58.78 Million
Market Cap Rank
#28964 Global
#9619 in USA
Share Price
$5.00
Change (1 day)
+0.00%
52-Week Range
$5.00 - $5.00
All Time High
$5.00
About

Medinotec Inc. engages in the research and development, production, and sale of medical devices for the treatment of vascular and airway diseases in South Africa, the United States, and internationally. The company offers semi-compliant percutaneous transluminal coronary angioplasty balloon catheters, suction dissectors, aortic perfusion and dilation catheters, chronic total occlusion catheters, … Read more

Medinotec Inc. (MDNC) - Net Assets

Latest net assets as of November 2025: $5.50 Million USD

Based on the latest financial reports, Medinotec Inc. (MDNC) has net assets worth $5.50 Million USD as of November 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.85 Million) and total liabilities ($1.35 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $5.50 Million
% of Total Assets 80.26%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility 56.14

Medinotec Inc. - Net Assets Trend (2022–2025)

This chart illustrates how Medinotec Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Medinotec Inc. (2022–2025)

The table below shows the annual net assets of Medinotec Inc. from 2022 to 2025.

Year Net Assets Change
2025-02-28 $4.27 Million +97.07%
2024-02-29 $2.17 Million -15.21%
2023-02-28 $2.56 Million +643.86%
2022-02-28 $-469.99K --

Equity Component Analysis

This analysis shows how different components contribute to Medinotec Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 91872500.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (February 2025)

Component Amount Percentage
Retained Earnings $918.12K 21.50%
Other Components $3.35 Million 78.50%
Total Equity $4.27 Million 100.00%

Medinotec Inc. Competitors by Market Cap

The table below lists competitors of Medinotec Inc. ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medinotec Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 2,167,171 to 4,270,829, a change of 2,103,658 (97.1%).
  • Net income of 2,159,473 contributed positively to equity growth.
  • Other factors decreased equity by 55,815.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $2.16 Million +50.56%
Other Changes $-55.81K -1.31%
Total Change $- 97.07%

Book Value vs Market Value Analysis

This analysis compares Medinotec Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 13.74x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2022-02-28 $-0.04 $5.00 x
2023-02-28 $0.22 $5.00 x
2024-02-29 $0.18 $5.00 x
2025-02-28 $0.36 $5.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medinotec Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 50.56%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 23.70%
  • • Asset Turnover: 1.34x
  • • Equity Multiplier: 1.59x
  • Recent ROE (50.56%) is above the historical average (6.03%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2023 -13.80% -35.29% 0.22x 1.76x $-608.34K
2024 -18.67% -8.06% 1.04x 2.22x $-621.41K
2025 50.56% 23.70% 1.34x 1.59x $1.73 Million

Industry Comparison

This section compares Medinotec Inc.'s net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $694,749,556
  • Average return on equity (ROE) among peers: -25.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Medinotec Inc. (MDNC) $5.50 Million -13.80% 0.25x $9.06 Million
Advanced Biomedical Technologies Inc (ABMT) $-4.46 Million 0.00% 0.00x $14.18K
Abbott Laboratories (ABT) $4.82 Billion 39.04% 1.31x $191.37 Billion
Acarix AB (publ) (ACIXF) $1.93 Million -127.02% 0.21x $26.42 Million
Adagio Medical Holdings, Inc Common Stock (ADGM) $-72.62 Million 0.00% 0.00x $4.05 Million
Adm Tronics Unltd (ADMT) $-12.69K 0.00% 0.00x $3.17 Million
Aethlon Medical Inc (AEMD) $-3.07 Million 0.00% 0.00x $2.79 Million
Acutus Medical Inc (AFIB) $126.58 Million -80.56% 0.52x $732.88K
Adapthealth Corp (AHCO) $2.07 Billion 7.56% 1.54x $914.25 Million
Allied Healthcare Products Inc. (AHPIQ) $8.88 Million -33.95% 1.22x $726.24
20/20 Biolabs, Inc. Common Stock (AIDX) $3.39 Million -59.65% 0.38x $9.18 Million